Stay updated on FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A sitewide NIH notice about website updates and terminology appears above the unchanged 403 Forbidden page.
    Difference
    1%
    Check dated 2026-10-26T16:45:28.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.1 to v3.7.2 while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-19T21:56:21.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0, while the page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-13T04:15:00.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the normal study details with a simple error page.
    Difference
    18%
    Check dated 2026-09-21T22:30:31.000Z thumbnail image
  5. Check
    59 days ago
    Change Detected
    Summary
    The page metadata was updated to revision v3.6.6, replacing the previous v3.6.5.
    Difference
    0.0%
    Check dated 2026-08-31T16:53:03.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    A funding attribution line '2019 ( U.S. NIH Grant/Contract )' was added, indicating NIH support for the study.
    Difference
    0.0%
    Check dated 2026-08-24T16:36:26.000Z thumbnail image

Stay in the know with updates to FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.